Abstract
The prognosis of patients with metastatic renal cell carcinoma (mRCC) has improved markedly with the introduction of molecular-targeted agents and immune checkpoint inhibitors. However, there are few reports on the outcome of systemic therapy for hemodialysis patients with mRCC. The purpose of this study is to evaluate the outcome of the systemic therapy for hemodialysis patients with mRCC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.